Friday, July 10, 2026

pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease

Pierre Fabre Medicament

Pierre Fabre Medicament patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

LAVAUR, FR HQ
176 Employees
EMA registrant Type
Company details
Status
Public
HQ
LAVAUR, FR
Employees
176
Programs
8
Drugs
13
Patents
0
Intelligence · Patents

Pierre Fabre Medicament patents

0 pharmaceutical patents indexed for Pierre Fabre Medicament. 0 expire within 24 months.

Pierre Fabre Medicament has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

No patents matched

Try a different expiry filter or check back as we index more USPTO records.

Frequently asked questions

How many patents does Pierre Fabre Medicament have?

0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Pierre Fabre Medicament patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.